Ohr Expects to Release Top-line Phase III Trials Next Year

Jason Slakter, MD, CEO, lays out a pivotal year for Ohr Pharmaceutical’s squalamine lactate, an intracellular treatment for wet AMD. Dr. Slakter reviews early results from a Phase II trial comparing squalamine/Lucentis combination therapy versus Lucentis/placebo. The company expects to have top-line data of a Phase III trial (called MAKO) in early 2018.